Treatment with a combination of two drugs could improve the quality of life of patients with cystic fibrosis. Results of two late-stage trials published in the New England Journal of Medicine showed that treatment with the two drugs – lumacaftor and ivacaftor – produced significant improvements in lung function, and also lowered the speed of pulmonary exacerbation as compared to placebo.